Individualizing treatment of patients with myeloma in the era of novel agents.
about
Diagnostic delay and complications for older adults with multiple myelomaA staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction.Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di MidolloBendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasoneInitial therapy in multiple myeloma: investigating the new treatment paradigm.IRF4: Immunity. Malignancy! Therapy?Current multiple myeloma treatment strategies with novel agents: a European perspectiveURI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Guidelines for the diagnosis and management of multiple myeloma 2011.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.Can multiple myeloma become a curable disease?Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
P2860
Q33698897-84D17D2B-894A-4314-BC49-F8C7AF44F3BCQ34077188-AECAAFA9-EC48-496A-B4A8-DDEC2BC465A5Q34184698-2F906860-AF8E-44BC-BEEF-3B9D2EA4DB39Q34255145-5C0120DE-EC80-4BB5-B37F-DE286926E7CFQ35551777-16C19D95-66C2-420F-BA00-2339000F0805Q36165279-4559050B-4DDA-4ED1-8FE3-DD045788099BQ37151207-F1D730AB-D6B4-4264-A25B-7A29DAEE7234Q37216380-BEF5CEC4-59A5-462C-80C5-1CA7EB53B8FAQ37268930-B2438357-C2F4-49D8-AC92-52915BD2D8EEQ37411805-9F1CE3E3-07D6-4764-841C-C960B190CAF6Q37454043-BCEA01D2-0264-4A5F-A900-C70802CC0E49Q37677935-A365118D-18F8-4D02-A743-040AA8EF7FE3Q37680154-0A90720C-BCCA-426E-B4BD-DC116322ECFEQ37851944-3557398A-A0F7-4453-B059-0FAD589F2030Q37875193-448BD05C-7FBA-49A9-A120-8AED13416A37Q38037600-E5B7C2B7-3E74-4D3E-A666-AAD30EDB3CA7Q38108391-67C9B4DD-1F51-4FF2-9A4C-564D857F7B05Q38139989-4BAD0FFE-E3CA-47FF-A0EE-0B7D35A4DB59Q38261677-4A6024D5-F896-40ED-89C7-DCE29BE00EE7Q38809384-AE7FC50F-C4FC-4F1C-9AD3-6F30E6387CDFQ39589735-E0E45CA3-C943-4B3B-9D9A-463E849301DCQ45323952-CED988FC-3CE3-41A7-ABCF-01465ABB0A1BQ47996009-6C53B50D-7492-4C10-B0E8-0E2E36C2C6FFQ48084283-5026F029-DDFC-4B9D-98A9-A3EBDD975747Q53155413-81CE2447-4E68-4D77-88AA-A91E49D67CCC
P2860
Individualizing treatment of patients with myeloma in the era of novel agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Individualizing treatment of patients with myeloma in the era of novel agents.
@en
Individualizing treatment of patients with myeloma in the era of novel agents.
@nl
type
label
Individualizing treatment of patients with myeloma in the era of novel agents.
@en
Individualizing treatment of patients with myeloma in the era of novel agents.
@nl
prefLabel
Individualizing treatment of patients with myeloma in the era of novel agents.
@en
Individualizing treatment of patients with myeloma in the era of novel agents.
@nl
P356
P1476
Individualizing treatment of patients with myeloma in the era of novel agents
@en
P2093
Douglas Joshua
Jean-Luc Harousseau
P304
P356
10.1200/JCO.2007.15.2546
P407
P577
2008-04-21T00:00:00Z